Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;5(1):27-30.
doi: 10.15420/cfr.2018.44.1.

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs

Thomas A Zelniker  1 , Eugene Braunwald  1
Affiliations
Review

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs

Thomas A Zelniker et al. Card Fail Rev. 2019 Feb.

Abstract

Patients with type 2 diabetes are at increased risk of developing heart failure, cardiovascular death and renal failure. The recent results of three large sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials have demonstrated a reduction in heart failure hospitalisation and progressive renal failure. One trial also showed a fall in cardiovascular and total death. A broad spectrum of patients with diabetes benefit from these salutary effects in cardiac and renal function and so these trials have important implications for the management of patients with type 2 diabetes. Selected glucagon-like peptide 1 receptor agonists have also been shown to reduce adverse cardiovascular outcomes.

Keywords: Diabetes; heart failure; renal function; sodium-glucose cotransporter 2 inhibitors.

PubMed Disclaimer

Conflict of interest statement

Disclosure: TAZ is supported by the German Research Foundation (Deutsche Forschungsgemeinschaft ZE 1109/1-1 to TAZ). EB has no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. SGLT2i Treatment Effects
Figure 2:
Figure 2:. Differential Treatment Effects of SGLT2i
Figure 3:
Figure 3:. Overview of Unfavourable and Favourable Effects of SGLT2i in Patients with Type 2 Diabetes
See this image and copyright information in PMC

References

    1. Gregg EW, Li Y, Wang J, Burrows NR et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514–23. doi: 10.1056/NEJMoa1310799. - DOI - PubMed
    1. Ahmad FS, Ning H, Rich JD et al. Hypertension, obesity, diabetes, and heart failure-free survival: the Cardiovascular Disease Lifetime Risk Pooling Project. JACC Heart Fail. 2016;4:911–9. doi: 10.1016/j.jchf.2016.08.001. - DOI - PMC - PubMed
    1. Benjamin EJ, Virani SS, Callaway CW et al. Heart disease and stroke statistics — 2018 update: a report from the American Heart Association. Circulation. 2018;137:e67–e492. doi: 10.1161/CIR.0000000000000558. - DOI - PubMed
    1. American Diabetes Association. 10. Microvascular complications and foot care: Standards of Medical Care in Diabetes — 2018. Diabetes Care. 2018;41(Suppl 1):S105–S18. doi: 10.2337/dc18-S010. - DOI - PubMed
    1. Gerstein HC, Miller ME et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59. doi: 10.1056/NEJMoa0802743. Action to Control Cardiovascular Risk in Diabetes Study Group. - DOI - PMC - PubMed

LinkOut - more resources